Amifostine Articles
Sun Pharma's fiscal 2nd-qtr profit soars 135%
10 November 2008
Caraco's launches Sun Pharma's generic Ethyol
14 April 2008
Pinnacle and MedImmune sign Ethyol distribution deal
25 February 2008
MedImmune's 4th-qtr income rises 7%
19 February 2007
MedImmune's 2nd-qtr 2006 loss deepens 43%
31 July 2006
MedImmune sees its 1st-qtr 2006 sales fall
15 May 2006
MedImmune posts 15% rise in sales
14 February 2005
MedImmune's 2nd-qtr plunges into loss
2 August 2004
Global peripheral neuropathy market worth $1B by 2012
19 April 2004
MedImmune plans for $2B sales in 2009
8 March 2004
Alza Corp revenues pushing $1 billion
1 February 2001
Alza revenues top $200 million mark
20 April 2000
US Biosciences halts lodenosine HIV trial after death of patient
15 October 1999
Ethyol approved for dry mouth in USA
1 July 1999
Ethyol approved for dry mouth in USA
25 June 1999
US Bioscience submit sNDA for Ethyol to FDA
21 January 1999
Healthy Second-Quarter Growth For US Drug Firms
29 July 1998
Latest Wave Of US 1st Quarter Results
7 May 1998
Trend For 1997 Strong Sales Continues In USA
5 February 1998
Ph II Data With US Biosciences' Ethyol
30 October 1997
US 3rd Quarter Results Show Strong Growth
22 October 1997
Solid Growth For US Firms Despite Strong $
24 July 1997
Alza To Purchase 4.9% Of US Bioscience
17 February 1997
Dutch Government Reimbursement Blacklist Rises To 35
9 December 1996
Australia Approves US Bioscience's Ethyol
16 September 1996
Ethyol Indications Extended
19 August 1996
US Drug Majors See 2nd-Half Double-Digit Growth
29 July 1996
USB, Alza Extend Product Collaboration
3 June 1996
US Firms' Strong 1st Qtr Lifts Share Prices
29 April 1996
US Launch For Ethyol
29 April 1996
Additional Indication For Alza's Ethyol In USA
25 March 1996
NCEs In 1995: A Good Range Of Novel Drugs
29 January 1996
US Bioscience and Alza strike deal for Ethyol
8 January 1996
US Bioscience's amifostine: ECCO 8
13 November 1995
US Bioscience gets Ethyol approval
23 October 1995
US Bioscience hear FDA news on Ethyol
16 October 1995
New York stock comment
19 June 1995
...And US Bioscience's Ethyol
19 June 1995
Eli Lilly Canada; Hexalen and Ethyol
8 May 1995
New Chemical Entities Round-Up For 1994
6 February 1995
US Bioscience To Resubmit NDA
9 January 1995
First Approval For Ethyol, But FDA Panel Says No
19 December 1994
1st Cytoprotectant Set For EU Approval
3 October 1994
US Bioscience Amends Ethyol NDA
25 July 1994
BIOPHARMACEUTICALS MARKET GROWING FAST
13 June 1994
ENCOURAGING DATA FROM ETHYOL TRIAL
30 May 1994
BETAFECTIN STARTS PHASE III TRIALS
17 January 1994
PHASE III DATA ON US BIO'S ETHYOL
29 November 1993
BIOTECH PRODUCTS INUS DEVELOPMENT
26 July 1993
BREAST CANCER US RESEARCH UPDATE
26 April 1993
US BIO TO FILE NEW NDA FOR ETHYOL?
29 March 1993
US BIO'S ETHYOL TRIAL
1 February 1993
US FINDS ETHYOL NDA "UNACCEPTABLE"
8 June 1992
SUPPORTIVE CARE DRUGS IN CANCER: ASCO DATA
25 May 1992
APPROVAL SETBACK FOR US BIOSCIENCE
10 February 1992
STOCK MARKET COMMENTARY: NEW YORK
10 February 1992
FAVORABLE FORECASTS FOR US BIOTECH
13 January 1992
Showing 1-62 of 62 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
